Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cemsidomide + dexamethasone + elranatamab
- Development stage
- Phase 1
- Lead developer
- C4 Therapeutics, Inc.
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Oral, Subcutaneous
01
Overview
cemsidomide + dexamethasone + elranatamab (Elrexfio) is an investigational combination regimen being developed for the treatment of relapsed/refractory multiple myeloma (RRMM). The regimen combines cemsidomide (CFT7455), an oral small-molecule molecular glue degrader (MonoDAC) that targets the transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos) via cereblon (CRBN) E3 ligase modulation; dexamethasone, a corticosteroid; and elranatamab (Elrexfio), an FDA-approved bispecific T-cell engager (TCE) targeting B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells. This combination is designed to synergistically enhance anti-myeloma efficacy by combining direct tumor cell degradation and robust T-cell activation with targeted T-cell redirection. The regimen is being evaluated in a Phase 1b clinical trial (NCT07280013) sponsored by C4 Therapeutics, with Pfizer supplying elranatamab.
- Other names
- CFT7455 + dexamethasone + ElrexfioCFT7455 + dexamethasone + elranatamabcemsidomide + dexamethasone + Elrexfio
02
Targets
CRBN (Cereblon)GR (Glucocorticoid receptor)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)CD3 (T-cell surface glycoprotein CD3)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on cemsidomide + dexamethasone + elranatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cemsidomide + dexamethasone + elranatamab.